Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial ribosomal protein L40 (MRPL40) is a nuclear-encoded protein that forms part of the large (39S) subunit of the mitochondrial ribosome in eukaryotes, where it is essential for protein synthesis within the mitochondrion[2][3]. The mammalian mitoribosome differs significantly from prokaryotic ribosomes in composition and sequence, with MRPL40 contributing to translation of mitochondrially encoded proteins, particularly those involved in oxidative phosphorylation. Defects or deletions in the MRPL40 gene are associated with mitochondrial diseases and are implicated in congenital syndromes such as velo-cardio-facial syndrome and DiGeorge syndrome[2][3]. There is currently no evidence that MRPL40 is a therapeutic target for small-molecule drugs or biologics[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosomal protein L40 (MRPL40).